THERAPEUTIC AGENTS, COMPOSITIONS, AND METHODS FOR GLYCEMIC CONTROL

摘要

The present invention relates in part to insulin proteins and pharmaceutical compositions having therapeutic advantages. The effectiveness of peptide and small molecule drugs is often limited by the half-life of such drugs in the circulation, as well as difficulties in obtaining substantially constant plasma levels. For example, the incretin GLP-I must be administered at relatively high doses to counter its short half-life in the circulation, and these high doses arc associated with nausea, among other things. Murphy and Bloom, Nonpeptide glucagon-like peptide 1 receptor agonists: A magic bullet for diabetes?